This article examines the mechanisms, potential causes, and practical management strategies for sweating during GLP-1 therapy
Menos comnmente, pancreatitis y problemas renales
Pharmacokinetics and toxicology of therapeutic proteins: Advances and challenges :advances and challenges
TABLE 2 [i] GLP-1RAs glucagon-like peptide-1 receptor agonists, GIP/GLP-1RAs dual glucose-dependent insulinotropic polypeptide receptor agonists, SGLT2 inhibitors sodium-glucose cotransporter-2 inhibitors, ASA American Society of Anesthesiologists, ESAIC European Society of Anaesthesiology and Intensive Care
Some people, however, feel that they would benefit from additional doses in-between, based on their individual symptoms and response to the injections
Compounders must discontinue production by the respective deadlines or face FDA enforcement